Risankizumab for Crohn's disease

In The Lancet, two new studies report randomised controlled trials of risankizumab for Crohn's disease. 1 D'Haens G Panaccione R Baert F et al. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022; 399: 2015-2030 Summary Full Text Full Text PDF Scopus (10) Google Scholar , 2 Ferrante M Panaccione R Baert F et al. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022; 399: 2031-2046 Summary Full Text Full Text PDF Scopus (7) Google Scholar In the first, Geert D’Haens and colleagues share the findings of the ADVANCE and MOTIVATE phase 3 trials comparing the efficacy and safety of risankizumab with placebo in the induction period. 1 D'Haens G Panaccione R Baert F et al. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022; 399: 2015-2030 Summary Full Text Full Text PDF Scopus (10) Google Scholar The intention-to-treat population included 850 patients (390 [46%] women, 460 [54%] men; median age 37·5 years [IQR 13·3]) for ADVANCE and 569 patients (276 [49%] women, 293 [51%] men; median age 39·6 years [13·3]) for MOTIVATE in hospital academic medical centres, clinical research units, and private practices. In the second, Marc Ferrante and colleagues report the results of the FORTIFY phase 3 trial comparing the efficacy and safety of risankizumab with placebo in the maintenance period. 2 Ferrante M Panaccione R Baert F et al. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022; 399: 2031-2046 Summary Full Text Full Text PDF Scopus (7) Google Scholar The intention-to-treat population included 462 patients (224 [48%] women, 238 [52%] men) in clinical centres. Risankizumab is a humanised monoclonal antibody targeting interleukin (IL)-23A, and these Articles are the first reports to show the therapeutic effect of IL-23-specific inhibition in phase 3 trials for patients with Crohn's disease, and to include the co-primary endpoints of clinical remission and endoscopic response. The studies showed that risankizumab was well tolerated and effective for maintenance of remission and as induction therapy in patients with moderately to severely active Crohn's disease. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trialsRisankizumab was effective and well tolerated as induction therapy in patients with moderately to severely active Crohn's disease. Full-Text PDF Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trialSubcutaneous risankizumab is a safe and efficacious treatment for maintenance of remission in patients with moderately to severely active Crohn's disease and offers a new therapeutic option for a broad range of patients by meeting endpoints that might change the future course of disease. Full-Text PDF Head and neck cancer: high-end technology is no guarantee of high-quality careAfter seven impressive wins of the Formula 1 World Championship, Lewis Hamilton was defeated in Abu Dhabi in December, 2021, by Max Verstappen, a young talented Dutch driver. In my opinion, Verstappen did not win because he had a faster car but because he was the better pilot and because he had support from a better strategic team. Full-Text PDF